MNTA: After perusing various docs, one gets the distinct impression that: 1. Sandoz/MNTA know more about a given batch of Copaxone than Teva or 2. Teva is being borderline deceitful or both.
In any event, I still believe this remains bullish for MNTA and still believe the perceived delay increases the likelihood of a SJ against Teva.
"If we don't succeed, we run the risk of failure." -Dan Quayle
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.